SCHEMBL8680473

SCHEMBL8680473

COC(=O)c1ccc2cc(O[Si](C)(C)C(C)(C)C)ccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.52
CA12 O43570 5/20 0.52
CA9 Q16790 5/20 0.52
PTPN11 Q06124 1/20 0.48
HGFAC Q04756 1/20 0.47
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
CYP19A1 P11511 1/20 0.46
LCK P06239 1/20 0.46
CA2 P00918 2/20 0.45
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44
KDM4E B2RXH2 1/20 0.44
PLAU P00749 2/20 0.43
PLG P00747 1/20 0.43
PLAT P00750 1/20 0.43
CA7 P43166 1/20 0.42
XDH P47989 1/20 0.42
CA14 Q9ULX7 1/20 0.42
NOTUM Q6P988 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3149926 0.97 CA1 (0.50) CA1CA12CA9PTPN11HGFAC
SCHEMBL8906116 0.86 CA1 (0.56) CA1CA12CA9CA2KDM4E
SCHEMBL4346540 0.84 L3MBTL1 (0.50) HTTMAPT
SCHEMBL9043929 0.80 CYP19A1 (0.44) PTPN11HGFACCYP11B1CYP11B2CYP19A1
SCHEMBL6625609 0.80 KDM4E (0.44) CA1CA12CA9PTPN11CA2
SCHEMBL18304558 0.80 KDM4E (0.44) CA1CA12CA9PTPN11CA2
SCHEMBL20046200 0.79 CA1 (0.43) CA1CA12CA9CA2HTT
SCHEMBL19810800 0.79 NOTUM (0.41) CA1CA12CA9CA2ALOX15
SCHEMBL19810798 0.79 NOTUM (0.41) CA1CA12CA9CA2ALOX15
SCHEMBL22002134 0.79 CA12 (0.47) CA1CA12CA9HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170282-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 US disclosed
US-20220339303-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. 2022-10-27 US disclosed
US-20200397927-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-12-24 US disclosed
US-20200397927-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-12-24 US disclosed
EP-3567029-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2019-11-13 EP disclosed
EP-3567029-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2019-11-13 EP disclosed
EP-2753605-B1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING INC (US) 2019-03-27 EP disclosed
EP-2753605-B1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING INC (US) 2019-03-27 EP disclosed
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-09-21 US disclosed
US-9550000-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2017-01-24 US disclosed
US-20140328756-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-11-06 US disclosed
WO-2013036869-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2013-03-14 WO disclosed
US-5707559-A PROVIDING A STABLE 1,2-DIOXETANE WHICH FORMS INTERMEDIATE UNSTABLE COMPOUNDS WHEN TRIGGERED TO REMOVE BLOCKING GROUPS BY ACTIVATING AGENT SO THAT UNSTABLE COMPOUND DECOMPOSES TO FORM LIGHT AND TWO CARBONYL COMPOUNDS TROPIX, INC. (US) 1998-01-13 US disclosed
EP-0595369-B1 Alkene compounds TROPIX INC (US) 1996-12-04 EP disclosed
US-5386017-A Can be converted to stable aryl substituted 1,2-dioxetanes which decompose when activated to produce light and carbonyl compounds BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1995-01-31 US disclosed
EP-0254051-B1 Chemiluminescent 1,2-dioxetane compounds UNIV WAYNE STATE (US) 1994-08-31 EP disclosed
EP-0595369-A1 Alkene compounds TROPIX, INC. (US) 1994-05-04 EP disclosed
US-4962192-A Chemiluminescent 1,2-dioxetane compounds BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1990-10-09 US disclosed
US-4857652-A Chemiluminescent 1,2-dioxetane compounds BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1989-08-15 US disclosed
EP-0254051-A2 Chemiluminescent 1,2-dioxetane compounds THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY (US) 1988-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170266326-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA1 85/4885CA12 138/4885CA9 482/4885
US-20250170282-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA1 85/4885CA12 138/4885CA9 482/4885
US-20140328756-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA1 85/4885CA12 138/4885CA9 482/4885
US-20220339303-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA1 85/4885CA12 138/4885CA9 482/4885
US-20200397927-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 CA1 85/4885CA12 138/4885CA9 482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.